Jonathan Treisman

2.3k total citations
31 papers, 1.1k citations indexed

About

Jonathan Treisman is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jonathan Treisman has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Immunology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jonathan Treisman's work include CAR-T cell therapy research (13 papers), Immunotherapy and Immune Responses (8 papers) and Immune Cell Function and Interaction (6 papers). Jonathan Treisman is often cited by papers focused on CAR-T cell therapy research (13 papers), Immunotherapy and Immune Responses (8 papers) and Immune Cell Function and Interaction (6 papers). Jonathan Treisman collaborates with scholars based in United States, Israel and United Kingdom. Jonathan Treisman's co-authors include R Cowherd, GE Shafer, Zelig Eshhar, Steven A. Rosenberg, Patrick Hwu, Dvorit Samid, Patrick Hwu, Michael L. Salgaller, Meenhard Herlyn and S A Rosenberg and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Jonathan Treisman

31 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonathan Treisman United States 14 675 602 425 243 147 31 1.1k
Inmaculada Rodríguez Spain 19 1.0k 1.5× 991 1.6× 285 0.7× 118 0.5× 121 0.8× 24 1.5k
Gavin Bendle United Kingdom 17 1.2k 1.7× 1.0k 1.7× 342 0.8× 397 1.6× 53 0.4× 29 1.5k
Katharina Bergerhoff United Kingdom 9 1.2k 1.7× 1.1k 1.7× 286 0.7× 121 0.5× 132 0.9× 10 1.5k
Elixabet Bolaños Spain 19 887 1.3× 972 1.6× 290 0.7× 146 0.6× 80 0.5× 33 1.4k
Jan L. Fisher United States 20 703 1.0× 825 1.4× 412 1.0× 56 0.2× 143 1.0× 37 1.3k
Maria-Elisabeth Goebeler Germany 13 803 1.2× 438 0.7× 268 0.6× 126 0.5× 288 2.0× 27 1.1k
Ehsan Ghorani United Kingdom 14 731 1.1× 534 0.9× 431 1.0× 87 0.4× 51 0.3× 31 1.3k
Isaac Kriley United States 5 983 1.5× 744 1.2× 297 0.7× 97 0.4× 112 0.8× 9 1.2k
Yukimi Sakoda Japan 17 1.2k 1.8× 898 1.5× 361 0.8× 269 1.1× 88 0.6× 27 1.7k
Brock Lanier United States 5 1.0k 1.5× 439 0.7× 294 0.7× 343 1.4× 36 0.2× 8 1.1k

Countries citing papers authored by Jonathan Treisman

Since Specialization
Citations

This map shows the geographic impact of Jonathan Treisman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Treisman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Treisman more than expected).

Fields of papers citing papers by Jonathan Treisman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Treisman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Treisman. The network helps show where Jonathan Treisman may publish in the future.

Co-authorship network of co-authors of Jonathan Treisman

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Treisman. A scholar is included among the top collaborators of Jonathan Treisman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Treisman. Jonathan Treisman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Izano, Monika A., Chenan Zhang, James L. Weese, et al.. (2023). Brief Report on Use of Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis. Clinical Lung Cancer. 24(4). 362–365. 6 indexed citations
2.
Treisman, Jonathan, et al.. (2021). Risk Factors for Cost-Related Delays to Medical Care Among Lymphoma Patients: A 22-Year Analysis of a Nationally Representative Sample. Clinical Lymphoma Myeloma & Leukemia. 21(7). e619–e625. 6 indexed citations
3.
Fishman, Mayer, Janice P. Dutcher, Joseph I. Clark, et al.. (2019). Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. Journal for ImmunoTherapy of Cancer. 7(1). 84–84. 41 indexed citations
4.
Wang, James, Kyle A. Udd, Regina A. Swift, et al.. (2016). Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. Supportive Care in Cancer. 24(7). 3105–10. 28 indexed citations
5.
Richards, John O., et al.. (2012). Flow cytometry assessment of residual melanoma cells in tumor‐infiltrating lymphocyte cultures. Cytometry Part A. 81A(5). 374–381. 12 indexed citations
6.
Choong, Nicholas W., et al.. (2011). Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia. American Journal of Otolaryngology. 33(3). 349–351. 21 indexed citations
7.
Douglas, Kenneth, Anne Parker, Patrick Hayden, et al.. (2011). Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. Bone Marrow Transplantation. 47(1). 18–23. 10 indexed citations
8.
Treisman, Jonathan, et al.. (2009). Systemic Therapy for Cutaneous Melanoma. Clinics in Plastic Surgery. 37(1). 127–146. 17 indexed citations
9.
Treisman, Jonathan, et al.. (2005). Ex vivo generation of genetically modified dendritic cells for immunotherapy: implications of lymphocyte contamination. Gene Therapy. 12(3). 259–271. 9 indexed citations
10.
Chinnasamy, Dhanalakshmi, Leslie J. Fairbairn, Jonathan Treisman, et al.. (2004). Lentivirus-Mediated Expression of Mutant MGMT P140K Protects Human CD34 + Cells Against the Combined Toxicity of O 6 -Benzylguanine and 1,3-Bis(2-Chloroethyl)-Nitrosourea or Temozolomide. Human Gene Therapy. 15(8). 758–769. 24 indexed citations
11.
Kershaw, Michael H., et al.. (2002). Increased functional expression of transgene in primary human lymphocytes using retroviral vectors modified with IRES and splicing motifs. Gene Therapy. 9(16). 1085–1092. 11 indexed citations
12.
Lum, Lawrence G., et al.. (2001). Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28–Costimulated T Cells—Phase I Clinical Trial. Journal of Immunotherapy. 24(5). 408–419. 32 indexed citations
13.
Royal, Richard E., Michael H. Kershaw, Jonathan Treisman, et al.. (2000). Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Therapy. 7(2). 284–291. 46 indexed citations
14.
Eshhar, Zelig, Gideon Gross, Tova Waks, et al.. (1995). T-Bodies: Chimeric T-Cell Receptors with Antibody-Type Specificity. Methods. 8(2). 133–142. 9 indexed citations
15.
Treisman, Jonathan, Patrick Hwu, Seijiro Minamoto, et al.. (1995). Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood. 85(1). 139–145. 65 indexed citations
16.
Treisman, Jonathan, Patrick Hwu, John R. Yannelli, et al.. (1994). Upregulation of Tumor Necrosis Factor-α Production by Retrovirally Transduced Human Tumor-Infiltrating Lymphocytes Using trans-Retinoic Acid. Cellular Immunology. 156(2). 448–457. 11 indexed citations
17.
Hwu, Patrick, GE Shafer, Jonathan Treisman, et al.. (1993). Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.. The Journal of Experimental Medicine. 178(1). 361–366. 207 indexed citations
18.
Fox, David A., Jonathan Treisman, Alice G. Bergman, et al.. (1991). Defective CD2 pathway T cell activation in systemic lupus erythematosus. Arthritis & Rheumatism. 34(5). 561–571. 26 indexed citations
19.
Treisman, Jonathan & Francis S. Collins. (1987). Adult Turner syndrome associated with chylous ascites and vascular anomalies. Clinical Genetics. 31(4). 218–223. 3 indexed citations
20.
Horwitz, Jerome P., et al.. (1980). Ethchlorvynol: potential of metabolites for adverse effects in man.. Drug Metabolism and Disposition. 8(2). 77–83. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Inmaculada Rodríguez Breakdown of academic impact, for papers by Gavin Bendle Breakdown of academic impact, for papers by Katharina Bergerhoff Breakdown of academic impact, for papers by Elixabet Bolaños Breakdown of academic impact, for papers by Jan L. Fisher Breakdown of academic impact, for papers by Maria-Elisabeth Goebeler Breakdown of academic impact, for papers by Ehsan Ghorani Breakdown of academic impact, for papers by Isaac Kriley Breakdown of academic impact, for papers by Yukimi Sakoda Breakdown of academic impact, for papers by Brock Lanier
Rankless by CCL
2026